CO6270213A2 - Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion - Google Patents

Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion

Info

Publication number
CO6270213A2
CO6270213A2 CO10047531A CO10047531A CO6270213A2 CO 6270213 A2 CO6270213 A2 CO 6270213A2 CO 10047531 A CO10047531 A CO 10047531A CO 10047531 A CO10047531 A CO 10047531A CO 6270213 A2 CO6270213 A2 CO 6270213A2
Authority
CO
Colombia
Prior art keywords
preparation
inhaled
unhibitor
depde
corticoesteroid
Prior art date
Application number
CO10047531A
Other languages
English (en)
Spanish (es)
Inventor
Roch Thibert
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of CO6270213A2 publication Critical patent/CO6270213A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO10047531A 2007-10-25 2010-04-22 Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion CO6270213A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32707P 2007-10-25 2007-10-25

Publications (1)

Publication Number Publication Date
CO6270213A2 true CO6270213A2 (es) 2011-04-20

Family

ID=40579006

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10047531A CO6270213A2 (es) 2007-10-25 2010-04-22 Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion

Country Status (19)

Country Link
US (1) US20100210611A1 (OSRAM)
EP (1) EP2211863A4 (OSRAM)
JP (1) JP2011500731A (OSRAM)
KR (1) KR20100072295A (OSRAM)
CN (1) CN101909626A (OSRAM)
AU (1) AU2008316283A1 (OSRAM)
CA (1) CA2701956A1 (OSRAM)
CO (1) CO6270213A2 (OSRAM)
CR (1) CR11439A (OSRAM)
DO (1) DOP2010000122A (OSRAM)
GT (1) GT201000107A (OSRAM)
IL (1) IL205182A0 (OSRAM)
MA (1) MA33705B1 (OSRAM)
MX (1) MX2010004529A (OSRAM)
NI (1) NI201000069A (OSRAM)
NZ (1) NZ584876A (OSRAM)
RU (1) RU2470639C2 (OSRAM)
WO (1) WO2009052624A1 (OSRAM)
ZA (1) ZA201002562B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012168907A1 (en) 2011-06-10 2012-12-13 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising revamilast and montelukast or zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
US20160339010A1 (en) 2014-01-22 2016-11-24 Takeda Gmbh Treatment of Partly Controlled or Uncontrolled Severe Asthma
CN108267531B (zh) * 2016-12-31 2022-01-11 天津金耀集团有限公司 一种环索奈德有关物质hplc测定方法
IT201900014178A1 (it) * 2019-08-06 2021-02-06 Genetic S P A Esteri del montelukast e loro formulazioni farmaceutiche

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US20040214805A1 (en) * 1999-11-02 2004-10-28 Smithkline Beecham Corporation Method and compositions for treating pulmonary diseases
US6528527B2 (en) * 2000-11-07 2003-03-04 Merck & Co., Inc. Method of treatment with a combination of a PDE4 inhibitor and a leukotriene antagonist
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
CN100346831C (zh) * 2001-09-19 2007-11-07 奥坦纳医药公司 Pde抑制剂与白三烯受体拮抗剂的并用药物
DE10237739A1 (de) * 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
PT1670482E (pt) * 2003-09-16 2014-03-12 Takeda Gmbh Utilização de ciclesonida para o tratamento de doenças respiratórias
WO2005040123A1 (en) * 2003-10-10 2005-05-06 Synhton B. V. Solid-state montelukast
CN100512813C (zh) * 2004-02-06 2009-07-15 Meda制药有限及两合公司 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
JP2008533174A (ja) * 2005-03-16 2008-08-21 エラン ファーマ インターナショナル リミテッド ナノ粒子ロイコトリエン受容体拮抗薬/副腎皮質ステロイド製剤
HRP20160373T1 (hr) * 2005-03-16 2016-05-06 Meda Pharma Gmbh & Co. Kg Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava
JP2009509980A (ja) * 2005-09-28 2009-03-12 メルク フロスト カナダ リミテツド 篩分けされたラクトースを含むエアゾール粉末製剤

Also Published As

Publication number Publication date
EP2211863A1 (en) 2010-08-04
EP2211863A4 (en) 2012-07-25
RU2010120806A (ru) 2011-11-27
MA33705B1 (fr) 2012-11-01
GT201000107A (es) 2012-03-13
RU2470639C2 (ru) 2012-12-27
CA2701956A1 (en) 2009-04-30
WO2009052624A1 (en) 2009-04-30
CN101909626A (zh) 2010-12-08
CR11439A (es) 2010-06-21
KR20100072295A (ko) 2010-06-30
IL205182A0 (en) 2010-11-30
ZA201002562B (en) 2011-06-29
NI201000069A (es) 2010-08-23
JP2011500731A (ja) 2011-01-06
WO2009052624A9 (en) 2010-11-25
MX2010004529A (es) 2010-05-10
AU2008316283A1 (en) 2009-04-30
NZ584876A (en) 2012-06-29
US20100210611A1 (en) 2010-08-19
DOP2010000122A (es) 2010-07-15

Similar Documents

Publication Publication Date Title
ECSP088653A (es) Formulacion farmacéutica para aerosoles con dos o más principios activos y al menos una sustancia tensoactiva
JP2007106777A5 (OSRAM)
NZ585856A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
BR112014029735A2 (pt) forma de dosagem e formulação de abediterol
PE20141036A1 (es) Nueva dosificacion y formulacion
AR079726A1 (es) Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
CL2023000998A1 (es) Formulación farmacéutica para inhalador presurizado de dosis medidas
RU2008124825A (ru) Органические соединения, включающие соль гликопиррония
AR091161A1 (es) Composicion farmaceutica para inhalacion, metodo, uso
CY1117596T1 (el) Φαρμακευτικeς συνθeσεις αερολyματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
BR112015027247A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores contendo as mesmas
JP2011500731A5 (OSRAM)
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
AR094287A1 (es) Metodos y composiciones para administracion de oxibutinina
WO2011093811A3 (en) Pharmaceutical preparations comprising formoterol and fluticasone
TR200907914A2 (tr) Kortlkosteroid içeren kuru toz formunda farmasötik bileşim.
WO2011093812A3 (en) Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
TR200909793A2 (tr) Tiotropyum, mometazon ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu.
AR098867A1 (es) Composición farmacéutica en polvo seco para inhalación
WO2011093810A3 (en) Dry powder pharmaceutical composition comprising tiotropium and mometasone
AR085443A1 (es) Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero

Legal Events

Date Code Title Description
FC Application refused